Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial
I'm PortAI, I can summarize articles.
Immutep Ltd. reports significant progress in its TACTI-004 Phase III trial for advanced non-small cell lung cancer, with 289 patients enrolled out of a target of 756. Over 120 clinical sites are active across 27 countries, including the U.S. The futility analysis for 170 patients is set for Q1 2026, with full enrolment expected by Q3 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments